Compare Incyte Corporation (INCY) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Snowflake Inc — how do they compare? Incyte Corporation trades at $117 (market cap $23.11B), while Snowflake Inc trades at $272 (market cap $95.09B). The key difference: Snowflake Inc is far larger — about 4.1× Incyte Corporation's market cap. Which is the better fit depends on your goals.
| INCY | SNOW | |
|---|---|---|
Market Cap | $23.11B | $95.09B |
Sector | Health | Technology |
52-Week High | $118.52 | $280.16 |
52-Week Low | $67.38 | $121.11 |
Enterprise Value | $19.13B | $94.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $117.39, up 0.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $112.78. The company reported strong Q1 2026 earnings of $1.81 per share, beating expectations, and maintains robust profitability with a net income margin of 26.71%. Recent developments include a collaboration with Halozyme for cancer therapy and positive regulatory updates for Opzelura in Europe.
Outlook remains positive driven by earnings growth and pipeline advancements, though risks include competitive pressures and reliance on key products. The stock offers potential upside to the high target of $140, supported by institutional interest and solid cash flow generation, but investors should monitor execution on upcoming Q2 results.
Snowflake (SNOW) trades at $271.73, up 1.05% with strong bullish technical signals and consistent earnings beats. The company shows robust revenue growth from $1.2B in 2022 to $3.63B in 2025, though profitability remains negative with a -23.79% net margin. Analyst sentiment is overwhelmingly positive with 80.77% buy ratings and a $299.91 consensus target, while recent news highlights AI Data Cloud expansion and enterprise adoption.
Snowflake presents a growth investment opportunity with accelerating AI platform adoption and 30% revenue targets, but faces execution risks in achieving profitability amid high valuation multiples. The stock's upside depends on converting revenue growth to positive earnings while navigating competitive cloud data market pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
